...
首页> 外文期刊>Bone marrow transplantation >Salvage chemotherapy with high-dose carboplatin plus etoposide and autologous peripheral blood stem cell transplant in male pure choriocarcinoma: a retrospective analysis of 13 cases.
【24h】

Salvage chemotherapy with high-dose carboplatin plus etoposide and autologous peripheral blood stem cell transplant in male pure choriocarcinoma: a retrospective analysis of 13 cases.

机译:男性纯绒毛膜癌大剂量卡铂联合依托泊苷和自体外周血干细胞移植抢救化疗:回顾性分析13例。

获取原文
获取原文并翻译 | 示例
           

摘要

Choriocarcinoma of testes is a very rare tumor with poor prognosis, usually presenting with high serum level of human chorionic gonadotropin (hCG>50,000 mIU/ml) and advanced hematogenous metastases. Data with salvage chemotherapy has been sparse, with few long-term survivors. Between April 1996 and October 2004, 184 patients with germ cell tumor were treated at Indiana University with salvage high-dose chemotherapy (HDCT) with autologous peripheral blood stem cell transplant. Thirteen had pure choriocarcinoma or choriocarcinoma syndrome (normal testes by palpation and ultrasound, normal serum alpha-fetoprotein, advanced hematogenous metastases and high level hCG). All patients had progressed following one or two lines of cisplatin combination therapy. HDCT regimen was carboplatin 700 mg/m(2) and etoposide 750 mg/m(2) intravenously given for 3 consecutive days. A second course was given after hematopoietic recovery, usually 3-4 weeks later. The median survival was 19 months (range 5-90). Six patients (46%) are alive and continuously disease free (cNED) at a median follow-up of 37 months (range 19-75). One additional patient who relapsed after HDCT and was treated with third line chemotherapy followed by two surgical resections of choriocarcinoma is currently alive NED at +90 months from HDCT. Long-term disease-free survival and potential cure is possible with HDCT in choriocarcinoma patients that progressed after standard cisplatin combination therapy.
机译:睾丸绒毛膜癌是一种非常罕见的肿瘤,预后较差,通常表现为人绒毛膜促性腺激素的血清水平高(hCG> 50,000 mIU / ml)和晚期血源性转移。挽救性化疗的数据很少,长期幸存者很少。在1996年4月至2004年10月之间,印第安那大学对184例生殖细胞肿瘤患者进行了自体外周血干细胞移植抢救性大剂量化疗(HDCT)。 13名患有纯绒毛膜癌或绒毛膜癌综合征(通过触诊和超声检查睾丸正常,血清甲胎蛋白正常,血行转移晚期和高水平hCG)。所有患者均接受一到两行顺铂联合治疗后进展。 HDCT方案是连续3天静脉给予卡铂700 mg / m(2)和依托泊苷750 mg / m(2)。造血恢复后通常要3-4周后再进行第二个疗程。中位生存期为19个月(范围5-90)。 6名患者(46%)存活且持续无病(cNED),中位随访时间为37个月(范围19-75)。 HDCT后又复发并接受三线化疗,随后两次手术切除绒毛膜癌的另一名患者目前距HDCT尚有90个月,仍存活NED。在标准顺铂联合治疗后进展的绒癌组织中,HDCT可能实现长期无病生存和潜在治愈。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号